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DowLate relapse of breast cancer can occur more than 25 years after primary diagnosis. During the intervening
years between initial treatment and relapse, occult cancers are maintained in an apparent state of dormancy
that is poorly understood. In this study, we applied a probabilistic mathematical model to long-term follow-up
studies of postresection patients to investigate the factors involved in mediating breast cancer dormancy. Our
results suggest that long-term dormancy is maintained most often by just one growth-restricted dangerous
micrometastasis. Analysis of the empirical data by Approximate Bayesian Computation indicated that patients
in dormancy have between 1 and 5 micrometastases at 10 years postresection, when they escape growth re-
striction with a half-life of <69 years and are >0.4 mm in diameter. Before resection, primary tumors seed at
most an average of 6 dangerous micrometastases that escape from growth restriction with a half-life of at least
12 years. Our findings suggest that effective preventive treatments will need to eliminate these small numbers
of micrometastases, which may be preangiogenic and nonvascularized until they switch to growth due to one
oncogenic mutation or tumor suppressor gene inactivation. In summary, breast cancer dormancy seems to be
maintained by small numbers of sizeable micrometastases that escape from growth restriction with a half-life
exceeding 12 years. Cancer Res; 70(11); 4310–7. ©2010 AACR.Introduction
The practice of administering systematic therapy (e.g., che-
motherapy, endocrine therapy, or treatment such as trastu-
zumab) to breast cancer patients after apparently curative
surgery is designed to eradicate their unseen micrometas-
tases. Yet these therapies are not wholly effective.
Late relapse is well documented in breast cancer. In many
cases, metastases develop without evidence of local recur-
rence, suggesting that the initial metastatic event occurred
before the original treatment (e.g., in ref. 1, after 5 years post-
resection, 91% of primary recurrences are at distant sites).
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dergo a phase of growth restriction where there is a balance
between cell proliferation, cell death, and cell migration.
Dormancy in cancer is a period of growth restriction of
patients' unseen micrometastases. It has been investigated
for some time with the aim of designing optimal systematic
therapies (e.g., refs. 6–11). Dormancy is a common phenom-
enon in breast cancer, yet the associated biological mechan-
isms are unknown.
Meng and colleagues (12) showed that at least one in three
of 36 breast cancer patients examined 8 to 22 years post-
resection, who were clinically regarded as cured and who
showed no other signs of disease recurrence, had circulating
tumor cells (CTC) in their blood. The CTCs were viable but
not proliferating, and died with a half-life of approximately
3 hours (12). Second and third blood tests, between 2 months
and 2 years later, suggested that CTCs remained at a steady
concentration (1–2 cells per 12 mL) in every patient; patients
seemed to harbor micrometastases in a growth-restricted
phase, which contain proliferating cells with the capacity
to replenish populations of CTCs. Experimental models of
metastasis have shown that dormancy may arise via at least
three mechanisms: solitary “dormant” cells (13, 14), which
may persist in a quiescent state for months or possibly years
postresection (15); nonvascularized nonangiogenic microme-
tastases (16–20), restricted to a size of 1 to 2 mm in diameter
(16); and vascularized micrometastases that are held at an
equilibrium size by action of the immune system (21–23).
In this study, by investigating a probabilistic mathemat-
ical model and applying it to empirical data, we aim toh. 
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breast cancer dormancy. Our model features as its variable
the number of unseen micrometastases in a postresection
breast cancer patient. The micrometastases are subject to
(a) growth event causing escape from growth restriction,
for example, via new genetic or epigenetic mutations in-
ducing switch to the angiogenic phenotype or escape from
immune system surveillance; (b) disappearance, often at-
tributed to random effects of high rate of cell apoptosis,
immune attack, or the effects of systematic therapy; and
(c) metastasis of disseminated cells to seed new microme-
tastases. (c) is plausible because of the number of CTCs in
patients' blood and because metastases are often observed
at multiple sites on late relapse, suggesting that residual
cancer cells had the capacity to metastasize before the
growth event. These events, all intrinsically random, shape
the dynamics of disease progression.
Mathematical analysis and computer simulations led us
to a hypothesis that explains the steady numbers of CTCs
observed by Meng and colleagues: small numbers of micro-
metastases maintain dormancy in most breast cancer pa-
tients from approximately 8 years postresection. We used
our model to establish quantitatively when data from two
long-term follow-up studies of postresection breast cancer
patients (12, 24) support this hypothesis.
Materials and Methods
(i) Model
Patients postresection can be in one of four states: all metas-
tases in growth restriction as micrometastases (“dormancy”);
one or more growing metastases (“growth”); detectable metas-
tases (“relapse”); or no residual cancer (“clearance”). A patient
without detectable or growing cancers at the time of resection
progresses between states in the following manner.
At time t postresection, the number of micrometastases
in the patient is n(t). At time of resection (t = 0), there are
nB micrometastases, where nB is the number of microme-
tastases seeded by the primary tumor taking nonnegative
integer values with probabilities determined by a Poisson
distribution,8 mean E[nB]. If nB > 0, the patient has dormancy.
As time increases, micrometastases undergo growth
events [n(t) → growth] at steady probabilistic rate κ per
micrometastasis per year. Once a growth event occurs, a mi-
crometastasis transforms into a growing metastasis; then, it
is only a matter of time until the growing metastasis be-
comes detectable and the patient relapses (growth → relapse
in time τ; the size of the micrometastasis in growth re-
striction phase determines τ). Micrometastases each dis-
appear [n(t) → n(t) − 1] at steady stochastic rate μ per
year, so a patient with dormancy may reach cancer clearance8 L. Willis, T.A. Graham, T. Alarcón, I.P.M. Tomlinson, K.M. Page. Predictions
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the patient.
In addition, suppose that the disseminated cells of micro-
metastases themselves metastasize [n(t) → n(t) + 1] at steady
probabilistic rate λ per micrometastasis per year. If λ > 0,
the number of micrometastases may increase, which renders
relapse more likely as there are more opportunities for
growth events.
The capacity of cancer cells to metastasize can be altered
in a reversible fashion depending on the microenvironment
from which they originate; for example, bone marrow–
derived human mesenchymal stem cells, when mixed with
breast cancer cells, transiently increase their metastatic abil-
ity (25). The parameter that accounts for this is pM, the
frequency with which micrometastases are independently
seeded in such environments. For a summary of parameters,
see Table 1. For mathematical descriptions, see Supplemen-
tary Materials.
Supposing that μ and λ are constant is a parsimonious
assumption in the absence of further information. Microme-
tastases are assumed independent: they do not influence one
another's progression [although the primary tumor may in-
hibit growth of metastases (13), the 1,000-fold smaller size
of micrometastases makes mutual inhibition among them
improbable]. If the growth event results from genetic altera-
tions, κ may increase with time either because the prolifera-
tion rate of cells within micrometastases gradually increases
by selection or because the growth event requires an accu-
mulation of genetic alterations; cases for which the assump-
tion κ constant is valid are addressed in Section (iii) of
Results. The time between growth and relapse (τ) was set
at 3 years; the median doubling time in 199 cases of growing
primary and metastatic breast cancer was 3.5 months (26),
which gives an estimated time of 3 years for micrometastases
to grow from 1 mm in diameter to a detectable size; study (5)
suggests that metastasis growth time is only 9 months.
(ii) Summary statistics for fitting the model by
Approximate Bayesian Computation
We used Approximate Bayesian Computation (refs. 27, 28;
for review, see ref. 29) to identify regions of the parameter
space of {λ, μ, κ, pM, E[nB]} that fit the following summary
statistics from empirical data simultaneously: (a) The cumu-
lative frequency of relapse from 5 years postresection from
the Early Breast Cancer Trialists' Collaborative Group (24) to
within a total squared deviation of ε (data used from EBCTCG
was a 15-year follow-up study of 11,796 women ages 50 to 69 y;
most high-grade recurrences occur in younger women and
within 5 y). (b) The prevalence of dormancy (defined as the
fraction of nonrelapse patients with micrometastases) ex-
ceeds 36% at 13 years postresection (to agree with the average
time of patient examination in ref. 12 and the fraction of CTC-
positive patients in ref. 12). An additional hypothetical sum-
mary statistic was also investigated: (c) The frequency of
cancer clearance among nonrelapse patients exceeds 15% at
13 years postresection. (c) is related to the accuracy with
which the assay in ref. 12 detects dormancy in patients; for
example, if the accuracy is such that between 35% andCancer Res; 70(11) June 1, 2010 4311
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we expect cancer clearance among nonrelapse patients to
exceed approximately 15% at 13 years postresection.
By using data from these studies, we made two important
assumptions about the empirical data: (a) that the CTC
count of Meng and colleagues (12) is representative of dor-
mancy (it remains to be proved that these CTCs are shed
from metastases that are derived from the primary tumor
or are eventually responsible for relapse) and (b) that re-
lapses >5 years postresection are due mostly to metastases
that have undergone growth restriction phase, rather than
to new independently initiated tumors.
(iii) Materials
The model was run numerically in two ways: (a) by the
Gillespie algorithm (ref. 30; a method for simulating stochas-
tic models that is exact in the sense that it avoids finite step
approximations) and (b) by numerically solving appropriate
differential equations (available on request).
Approximate Bayesian Computation proceeded as follows.
Points (2 × 108) were sampled from a uniform prior distribu-
tion over the parameter space {λ, μ, κ, pM, E[nB]} < [0, 0.3] ×
[0, 0.3] × [0, 0.1] × [0, 1] × [0, 50]. For each sample from
parameter space, the summary statistics were simulated by
running the model 8,847 times (8,847 is the approxi-
mate number of patients remaining in the EBCTCG study
after τ = 3 years, by which time we supposed all patients
with growing metastases on resection to have relapsed).
If the simulated summary statistics fitted (a) and (b) of
Section (ii), the point was “accepted”; otherwise, it was
“rejected.” Frequency plots of accepted points approximateCancer Res; 70(11) June 1, 2010
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distribution and data (a) and (b).
The following estimates of P (D, f ), the number of cells that
proliferate per hour in a micrometastasis of diameter
D (mm), where f is the fraction of cancer cells that are viable
(i.e., able to proliferate) in the vascularized region of micro-
metastases, when micrometastases are (a) vascularized or
(b) nonvascularized, were used in Sections (iii) and (iv) of
Results. If a micrometastasis is approximately spherical of
diameter D (mm), the volume of its vascularized region is
πD3/6 when fully vascularized, and π(D3 − (D − 0.2)3)/6
when nonvascularized (it is well documented that only cells
within 0.1 mm of a blood supply are sufficiently supplied
by oxygen and nutrients to proliferate). The vascularized
region of a micrometastasis is assumed to be packed with
cancer cells, as supported by the high proportion of Ki67+
cells (a proliferative maker) in lymph node micrometastases
from breast cancer patients (see Supplementary Materials).
Each cancer cell occupies a spherical space of diameter
20 μmand the viable fraction f proliferate (i) once per 24 hours
(31) giving a high estimate of P (D, f ), or (ii) once per 5 days
giving a medium estimate of P (D, f ). [Cell proliferation rates
in nonvascularized tumors are comparable to proliferation
rates in vascularized tumors (16, 19), although there is evi-
dence that the proliferation rate is lower if the micrometasta-
sis is growth restricted by the immune system (23).] A high
estimate of P (D, f ) is therefore 1/24 × 1/(4 π 10−6/3) × π D3/6
× f < 5,000 f D3 [(a)—vascularized] or 104 × π(D3 − (D − 0.2)3)/6 ×
f < 5,000 f (D3 − (D − 0.2)3) [(b)—nonvascularized]. Similarly, a
medium estimate of P (D, f ) is 1,000 f D3 [(a)—vascular-
ized] or 1,000 f (D3 − (D− 0.2)3) [(b)—nonvascularized].Table 1. Parameter meanings and information related to their empirical values in breast cancerParameter Meaning Information from literatureE[nB] Average number of micrometastases
at or soon after resectionThe number of micrometastases on resection nB is Poisson
distributed. This assumes the nB micrometastases are seeded
by the primary tumor.λ Metastasis rate of cells of
micrometastases (per year)<106 cells from cancer cell lines are administered to mice to
initiate tumors (19, 39). In breast cancer dormancy, patient data
suggest that at least 1.5 × 106 CTCs are disseminated per year
(see NOTE). Then CTCs may be of a number large enough to
seed micrometastases at a consequential rate per year.μ Disappearance rate of
micrometastases (per year)Spontaneous regression of tumors is well documented (40–44):
In a large study of benign colon polyps, 18% disappeared
within 5 y (45), a rate of 4% per year (here μ > 0.04). In early
years, disappearance may be due to therapy.κ Growth event rate of
micrometastases (per year)Mechanism unknown. Possibly due to genetic alterations
causing angiogenesis (16) or escape from immune control
[ref. 23; Section (iii) of Results].pM Frequency with which micrometastases
are seeded in environments that
confer metastatic ability to their cellsThe metastatic ability of breast cancer cells is transiently
increased when mixed with human mesenchymal stem
cells derived from bone marrow (25). Therefore, pM < 1.NOTE: Calculated from the lower bound on CTCs of 500 and the CTC average death rate of <3 h (16), the number of CTCs
disseminated per year exceeds 500/3 × 24 × 365 = 1.46 × 106 [see Section (iv) of Results].Cancer Research
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(i) The number of micrometastases tends to 1 after long
time periods
Early mathematical analysis and computer simulations
show that the frequency distribution of the number of mi-
crometastases n among dormancy patients converges to a
distribution that no longer changes with time. Further, for
the whole volume of parameter space, this limiting distri-
bution is peaked at n = 1 micrometastasis (detailed in
Supplementary Materials and ref. 32). The question that
determines the validity of our hypothesis is “Do para-
meters that fit the summary statistics (a) and (b) of Sec-
tion (ii) of Materials and Methods also give convergence to
a sharply peaked stationary distribution within approxi-
mately 8 years of resection?”
(ii) Long-term dormancy is maintained by 1 to 5
micrometastases when the growth event occurs with a
half-life of less than 69 years
The model's fit to relapse data (a) in Section (ii) of Materi-
als and Methods is shown in Supplementary Material for the
total squared deviation ε = 0.001 and ε = 0.0005. The follow-
ing results are for ε = 0.001; they are only marginally per-
turbed for ε = 0.0005 and ε = 0.00025 (results not shown).
Shaded regions of Fig. 1 show, for all accepted values of κ,
the frequencies with which dormancy patients have less than
or equal to 3, 5, or 10 micrometastases at 10 and 20 years
postresection; the final column shows the frequencies with
which patients have more than 20 micrometastases at 10
and 20 years postresection. We see that for any accepted
value of κ exceeding 0.01 (equivalently, thinking of growth
restriction as “life” and escape from growth restriction as
“death,” micrometastases escape from growth restriction
with a half-life of 69 years or less), dormancy patients surviv-
ing beyond 10 years postresection have less than or equal towww.aacrjournals.org
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accepted value of κ exceeding 0.03 (micrometastases escape
from growth restriction with a half-life of 23 years or less),
more than 80% of dormancy patients have between 1 and
3 micrometastases from 10 years postresection. For any ac-
cepted value of κ < 0.003 (micrometastases escape from
growth restriction with a half-life >230 years), dormancy pa-
tient have more than 20 micrometastases at 10 years postre-
section with probability >20%.
There is a reciprocal relationship between accepted values
of κ and E[nB] (see Fig. 2, κ × E[nB] ≈ 0.06). κ is greater than
0.01 (or 0.03) if and only if E[nB] is less than or equal to 6 (or
3 respectively), and κ is less than 0.003 if and only if E[nB] is
greater than 20. This suggests a second way of validating
or invalidating the hypothesis: by finding the average number
of dangerous micrometastases among patients who do not
have detectable or growing metastases on resection.
The medians and the ranges of the marginal posterior
distributions generated by Approximate Bayesian Compu-
tation are in Table 2 (see Supplementary Materials for
plots of the marginal posteriors). The range of the margin-
al posterior for κ is [9 × 10−4, 0.06], meaning microme-
tastases escape from growth restriction with a half-life
exceeding 12 years. The lower bound is determined by
the upper bound (50) of the prior distribution over E[nB];
as the true upper bound for E[nB] is unknown, calculating
a Bayes factor to assess whether κ > 0.01 would be unin-
formative. However, if statistic (c) of Section (ii) of Materi-
als and Methods is added to summary statistics (a) and
(b), the range of κ is dramatically refined to [0.005, 0.06]
(see Fig. 2) and then the following statement can be made:
In excess of 40% of patients with dormancy who survive be-
yond 10 years postresection have less than 5 micrometastases
(see Fig. 1). Information not only from dormancy-detecting
assays, but further on the accuracy of these assays, would
allow a more informative statistical analysis.Figure 1. Probabilities associated with the number of micrometastases in dormancy patients. The shaded regions correspond to probabilities that the
number of micrometastases in dormancy patients are less than or equal to 3 (P{n ≤ 3}), 5 (P {n ≤ 5}), 10 (P{n ≤ 10}), or greater than 20 (P{n ≥ 21}) at
10 y postresection (top row) and 20 y postresection (bottom row), for all accepted parameters generated by an Approximate Bayesian Computation using
summary statistics (a) and (b) of Section (ii) of Materials and Methods.Cancer Res; 70(11) June 1, 2010 4313
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Suppose that growth events are triggered by genetic muta-
tions in the dividing cells of micrometastases. In two cases,
the rate of growth-phenotype mutations m per cell division
in a micrometastasis of diameter D (mm) and fraction f of
cancer cells that are viable in vascularized regions, along with
estimates of the number of cells that proliferate per hour,
P (D, f ), can be used to estimate κ. The cases are as follows:
1. Switch to the growth phenotype requires 1 mutation
(1 hit). This could correspond to 1 oncogenic mutation.
Then, κ = m × [365 × 24 × P (D, f )].
2. Switch to growth phenotype requires 2 mutations
(2 hits) and the size of the micrometastasis satisfies
certain constraints (see Supplementary Materials).
This could correspond to the inactivation of two alleles
in a tumor suppressor gene. For example, when m1
and m2 are the rates of the first and second mutations
per cell division, respectively, when the first mutation
is neutral, and when the total number of viable cells
in the micrometastasis exceeds 1/√m2 and is less
than 1/m1, then κ = m1 × √m2 × [365 × 24 × P (D, f )]
(refs. 33, 34).
Figure 3 shows how estimates of κ depend on the muta-
tion rate m for cases 1 and 2 when micrometastases are (a)Cancer Res; 70(11) June 1, 2010
Researc
on Novembecancerres.aacrjournals.org Downloaded from vascularized (thick lines) and (b) nonvascularized (thin lines).
The solid lines are upper bounds on κ [from the high
estimate of P (D, f )] for different values of D and f. The dashed
lines are estimates of κ [from the medium estimate of P (D, f )].
In Supplementary Materials, serial sections of lymph
node micrometastases from breast cancer patients show
that at least 20% of cancer cells are proliferating, so at least 20%
are viable and f > 0.2. Experimentally determined point muta-
tion rates in various normal cell types (corresponding to the
1-hit case) are around 10−9 per basepair per cell division
(35–37). The rate of mutation of an allele (the 2-hit case) is
normally assumed to be 10−7 per allele per cell division in
mathematical models. The range for κ identified in Section
(ii) of Results of [0.01, 0.06] places mutation rates close to ex-
perimentally determined mutation rates for D = 2 mm, 0.2 ≤
f ≤ 0.8; however, the same is true when κ is in the range
[0.003, 0.01].
(iv) Estimates suggest that a single micrometastasis
must have diameter exceeding 0.4 mm to account for
the CTCs
More than a decade postresection, results of Meng and
colleagues (12) suggest at least 500 CTCs are in the blood
of dormancy patients.9 From measurements of the decline
in a patient's CTC count on the removal of their primary
breast cancer, the average life span of a CTC was roughly
estimated as 1.5 to 3 hours (12). Thus, the total number
entering the blood is at least 500/3 or approximately 200
per hour (100% of CTCs were detected) or 5,000/3 or approx-
imately 2,000 per hour (10% of CTCs were detected).
The total number of cancer cells that proliferate per hour
in each dormancy patient must exceed the number of CTCs
entering the blood per hour; otherwise, the residual cancer
would disappear rapidly. The total number of cancer cellsThe assay (12) extracted 1-2 CTCs from 12.5mL of blood. As there is approx-
ately 6 liters of blood in the human body, a lower bound on the total num-9
imTable 2. Statistics of the marginal posterior
distributions of accepted values generated by
Approximate Bayesian Computation using
summary statistics (a) and (b) of Section (ii) of
Materials and MethodsParameter Median Rangeκ 0.0063 9.2 × 10−4 to 0.058
E[nB] 10 1.0–50ber of CTCs in the blood is 6,000/12.5 or approximately 500 CTCs.h. 
r 24, 2020. © 2010 American Figure 2. Reciprocal relationship
between κ and E[nB]. Gray-scale
maps (small values are black,
large values are white) of the joint
marginal posteriors of κ and E[nB]
of accepted parameters using
summary statistics (a) and (b) (left)
and summary statistics (a) to (c)
(right)—see Section (ii) of Materials
and Methods. In both plots,
there is a reciprocal relationship
between κ and E[nB] such that
κ × E[nB] ≈ 0.06, and accepted
values of κ are restricted to the
region κ < 0.06. The addition of
summary statistic (c) restricts κ to
the region 0.005 < κ < 0.06.Cancer Research
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of diameter D is n × P (D, f ). This specifies lower bounds on
D given f in a patient with n micrometastases as shown in
Fig. 4, for high and medium estimates of P (D, f ), for four
cases: (i) the assay sensitivity was high (100% of CTCs were
detected); (ii) the assay sensitivity was medium (10% of CTCs
were detected); (a) micrometastases are vascularized and (b)
micrometastases are nonvascularized.
When only a single micrometastasis persists, the lower
bounds suggest its minimum diameter is 0.4 mm [100%
of CTCs were detected, high estimates of P (D, f ), f =
0.8]; more realistic lower bounds are 1 to 2.1 mm [10%
of CTCs were detected, medium estimates of P (D, f ), f =
0.8]. The minimum diameter of 0.4 mm does not change
much when, rather than 1 micrometastasis, up to 5 micro-
metastases persist.
Figure 4 indicates that a single nonvascularized micro-
metastasis of diameter 1 to 2 mm can account for the
CTCs in patients' blood unless (a) the sensitivity of the
CTC assay is medium-low (less than 10% of CTCs are de-
tected), the proliferation rate P (D, f ) is medium-low (via-
ble cancer cells divide less often than once per 5 days),
and f < 0.8 (less than 80% of cancer cells in vascularized
regions are viable); or (b) the sensitivity of the CTC assay
is medium-low and f < 0.2; or (c) the proliferation rate P
(D, f ) is medium-low and f < 0.1. These estimates could be
improved if the sensitivity of the assay detecting CTCs and
the exit rate of CTCs from the blood were known. Supple-
mentary Materials contains a table of the minimum num-
ber of micrometastases necessary to account for the CTCs
when D = 2 or 3 mm.www.aacrjournals.org
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Breast cancer is infamous for long gaps between primary
treatment and recurrence. Improvements in systematic ther-
apy are increasing the frequency with which patients survive
5 years postdiagnosis (24) while breast cancer is already the
most frequently diagnosed cancer in women in the Western
world. Yet, current systematic therapies improve prognosis
beyond 5 years only marginally (24, 38): elucidating the
causes of dormancy and subsequent relapse is becoming a
priority problem.
Analyses of our model led to the following hypothesis:
long-term breast cancer dormancy is maintained by a small
number, between 1 and 3—most frequently just 1, of danger-
ous micrometastases (dangerous micrometastases are those
which can cause relapse). The hypothesis would account for
the steady, similar number of CTCs observed by Meng and
colleagues over time and in different patients from approxi-
mately 8 years postresection, subject to the condition that
the persisting undetectable micrometastases are sizeable,
that is, their diameters exceed 0.4 mm considerably. This
condition is met if the micrometastases are preangiogenic
and nonvascularized, for then their limiting size is 1 to
2 mm (16–18). However, the lower threshold of the diameter
may vary upward above 2 mm depending on the density and
proliferation rate of cancer cells in micrometastases and the
sensitivity of the assay of Meng and colleagues; thus, this
condition ought to be checked when more empirical data re-
lated to these variables are available.
The validity of the hypothesis depends strongly on the
time scale of growth restriction of dormancy maintainingFigure 3. Mutation rates are in a plausible range. Plots illustrate how estimates for κ depend on the mutation rate per cell division m, supposing
that the switch to growth phenotype is due to one oncogenic mutation (1 hit) or two mutations in a tumor suppressor gene (2 hits, 1st neutral)—see
Section (iii) of Results. Thick/thin lines are for (a) vascularized/(b) nonvascularized micrometastases. Solid/dashed lines are for upper bounds/estimates of
κ using high/medium estimates of P (D, f ) [see Section (iii) of Materials and Methods], where values of D (micrometastasis diameter) and values of f (fraction
of cancer cells that are viable in vascularized regions) are indicated on each plot. Thick and thin lines coincide in the graphs of the right-hand column.Cancer Res; 70(11) June 1, 2010 4315
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appear and their cells metastasize to seed new micrometas-
tases slowly over years or decades, our analysis showed that
micrometastases escape growth restriction with a half-life
exceeding 12 years; if, further, the half-life is found to be less
than 23 years, this will provide firm evidence for our hypo-
thesis, with the additional consequence that the average
number of dangerous micrometastases on resection among
patients without detectable or growing metastases is 3 or
less. If it were possible to watch a sample of human micro-
metastases switching to growth phenotype, the half-life could
be measured. Perhaps more instructive is the following find-
ing: If the half-life of escape from growth restriction is found
to be less than 69 years, the majority of dormancy patients
have between 1 and 5 micrometastases from 10 years post-
resection, and the average number of dangerous micrometas-
tases on resection among patients without detectable or
growing metastases is 6 or less. Switch to growth phenotype
on these time scales agrees roughly with experimentally mea-
sured mutation rates supposing that either one oncogenic
mutation or mutations in two alleles (presumably in tumor
suppressor genes) cause the switch.
We urge caution in treating the bounds stated here as
inflexible: they should be treated as approximations to be
refined with further experimental data. Of particular use
for this and a more informative statistical analysis would
be the results of Meng and colleagues independently cor-
roborated with a system where either the specificity for
detecting CTCs in the blood or the effectiveness for
detecting dormancy in a patient was known. Our exposi-Cancer Res; 70(11) June 1, 2010
Researc
on Novembecancerres.aacrjournals.org Downloaded from tion makes it clear how the quantitative bounds can be
refined.
On the basis of our study, we predict that effective preven-
tive treatments for patients with long-term dormancy will be
those targeted at eradicating the proliferating cells of small
numbers of micrometastases or preventing the growth of
these micrometastases. These micrometastases may not have
formed at time of early systematic therapy. Screening patients
for dormancy and testing effectiveness of treatment could be
achieved by measuring patients' CTC counts or by measuring
disseminated tumor cell counts in bone marrow aspirates.
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OnlineFirst 05/25/2010.Figure 4. The hypothesis implies that the diameter of micrometastases exceeds 0.4 mm. The plots illustrate how the minimum diameter of
micrometastases D (mm) depends on both the number of micrometastases n in a patient from approximately 8 y postresection and the fraction f
of the vascularized tissue of micrometastases that is occupied by cancer cells, when micrometastases are (a) vascularized and (b) nonvascularized.
This lower bound on D is estimated from patients' CTC counts [see Section (iv) of Results]. Thin/thick lines are for (i) medium/(ii) high sensitivity of
CTC detection assay; solid/dashed lines are for high/medium estimates of P (D, f ) [see Section (iii) of Materials and Methods].Cancer Research
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